MétaCan
Menu
Back to cohort

Application of New Bioequivalence Testing Procedures To Tacrolimus Formulations in Stable Kidney Recipients: Global Regulatory Impact.

2014· article· en· W2772181388 on OpenAlexaboutno aff
Rita R. Alloway, Jennifer Trofe‐Clark, Uwe Christians, A. Wiland, Roy D. Bloom

Bibliographic record

VenueTransplantation · 2014
Typearticle
Languageen
FieldMedicine
TopicRenal Transplantation Outcomes and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsBioequivalenceCmaxTacrolimusMedicinePopulationPharmacologyGeneric drugInnovatorTransplantationPharmacokineticsInternal medicineDrugEnvironmental healthLawPolitical science

Abstract

fetched live from OpenAlex

Bioequivalence(BE) studies are an integral component of innovator and generic drug approval processes. Worldwide regulatory bodies have and continue to modify BE testing approaches for narrow therapeutic index(NTI) drugs such as tacrolimus. Modifications of BE approaches for NTI drugs essentially include two approaches 1)Direct tightening of average BE limits and 2) reference scaled average BE(RSCABE) based upon the within subject variability of the innovator product in healthy volunteers. The transplant community has encouraged testing in the transplant population. A recent publication of a prospective, two-center, randomized, two-period, two sequence, crossover, steady-state pharmacokinetic study comparing Sandoz generic tacrolimus (TS) vs Prograf (TP) in stable renal transplants revealed the following. The TS:TP ratio for AUC 0-12 was 1.02 with a 90% CI of 97-108% and Cmax was 1.09 with a 90% CI of 101-118%. Methods: Various BE testing approaches were applied to these data in stable renal transplants including tighter BE limits and RSCABE. Results: In the renal transplant population, tighter average BE limits for most regulatory bodies (Health Canada, South Africa, Asia and Latin America) were met for AUC and Cmax, however the Cmax did not meet 2010 regulatory standards of the EMA and the Danish Medicine Agency due to Cmax CI outside the 90.0-111.11% approval range and by not including 100% respectively. However in 2013, the EMA Efficacy Working Party recommended acceptable Cmax CI for tacrolimus of 80-125%. Calculations for RSCABE resulted in within subject variability of the innovator product (TP) of 14.9% and 24.2% for AUC and Cmax respectively. Using the RSCABE procedure, the 90% CI to meet BE standards for AUC was 86-117% and Cmax was 80-125%. Conclusion: TS in renal transplants met all current FDA and EMA modified bioequivalence criteria. Also, application of RSCABE to the variability of 24.2% of TP Cmax in the renal transplants showed that the confidence interval of 80-125% is acceptable and allows for adjustment to the variability of the innovator product, TP, in transplant recipients. The RSCABE approach dynamically adjusts to the variability of tacrolimus PK parameters of renal transplants, and may be more appropriate than fixed BE acceptance limits. DISCLOSURES:Wiland, A.: Employee, Novartis. McCague, K.: Employee, Novartis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.106
metaresearch head score (Gemma)0.095
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.106
Threshold uncertainty score0.561

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1060.095
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0040.003
Science and technology studies0.0010.004
Scholarly communication0.0020.002
Open science0.0020.002
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0010.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.332
Teacher spread0.307 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueTransplantationSame topicRenal Transplantation Outcomes and TreatmentsFrench-language works237,207